Cargando…
Current and emerging pharmacological therapy for non-alcoholic fatty liver disease
The main treatment of patients with non-alcoholic fatty liver disease (NAFLD) is life style modification including weight reduction and dietary regimen. Majority of patients are safely treated with this management and pharmacologic interventions are not recommended. However, a subgroup of NAFLD pati...
Autor principal: | Eshraghian, Ahad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698243/ https://www.ncbi.nlm.nih.gov/pubmed/29204050 http://dx.doi.org/10.3748/wjg.v23.i42.7495 |
Ejemplares similares
-
The Association between Angiotensin II Type 1 Receptor Gene A1166C Polymorphism and Non-alcoholic Fatty Liver Disease and Its Severity
por: Eshraghian, Ahad, et al.
Publicado: (2018) -
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
por: Francque, Sven, et al.
Publicado: (2019) -
Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
por: Basheer, Maamon, et al.
Publicado: (2023) -
Non-alcoholic fatty liver disease in women – Current knowledge and emerging concepts
por: Eng, Pei Chia, et al.
Publicado: (2023) -
The growing burden of non-alcoholic fatty liver disease on mortality
por: Cho, Ju-Yeon, et al.
Publicado: (2023)